Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC increased its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 22.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,102 shares of the specialty pharmaceutical company’s stock after acquiring an additional 743 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Jazz Pharmaceuticals were worth $505,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of JAZZ. IFP Advisors Inc purchased a new position in shares of Jazz Pharmaceuticals in the fourth quarter valued at $25,000. Quadrant Capital Group LLC increased its holdings in Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after acquiring an additional 101 shares in the last quarter. Elequin Capital LP raised its position in Jazz Pharmaceuticals by 677.8% during the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock worth $26,000 after acquiring an additional 183 shares during the last quarter. CoreFirst Bank & Trust purchased a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at about $28,000. Finally, Allianz SE purchased a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at about $29,000. 89.14% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on JAZZ. Truist Financial lifted their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a research report on Thursday, March 6th. JPMorgan Chase & Co. boosted their price target on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Needham & Company LLC restated a “buy” rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday. Morgan Stanley decreased their price objective on Jazz Pharmaceuticals from $183.00 to $166.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 7th. Finally, Robert W. Baird dropped their price objective on Jazz Pharmaceuticals from $167.00 to $155.00 and set an “outperform” rating for the company in a research report on Wednesday, May 7th. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $184.00.

Jazz Pharmaceuticals Trading Down 0.2%

NASDAQ JAZZ opened at $110.29 on Friday. The company has a market cap of $6.80 billion, a P/E ratio of 15.53, a P/E/G ratio of 1.04 and a beta of 0.33. Jazz Pharmaceuticals plc has a 12 month low of $95.49 and a 12 month high of $148.06. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The company has a 50-day moving average of $107.72 and a 200-day moving average of $120.66.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.65 by ($2.97). The company had revenue of $897.84 million during the quarter, compared to analysts’ expectations of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. Jazz Pharmaceuticals’s revenue for the quarter was down .5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.68 earnings per share. As a group, equities analysts predict that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current year.

Insider Transactions at Jazz Pharmaceuticals

In other news, Director Seamus Mulligan purchased 100,000 shares of the stock in a transaction on Friday, May 9th. The stock was purchased at an average price of $98.26 per share, with a total value of $9,826,000.00. Following the completion of the transaction, the director now owns 100,000 shares in the company, valued at approximately $9,826,000. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Bruce C. Cozadd sold 500 shares of Jazz Pharmaceuticals stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $107.90, for a total value of $53,950.00. Following the completion of the transaction, the chief executive officer now directly owns 438,473 shares in the company, valued at $47,311,236.70. This represents a 0.11% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 3,000 shares of company stock worth $355,925 in the last ninety days. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.